Bone Marrow News and Research RSS Feed - Bone Marrow News and Research

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.
Immunosuppressive drugs increase risk of myeloid disorders among IBD patients

Immunosuppressive drugs increase risk of myeloid disorders among IBD patients

Immunosuppressive drugs called thiopurines have been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among inflammatory bowel disease (IBD) patients. [More]
States of Maine and Rhode Island add SCID to newborn screening panels

States of Maine and Rhode Island add SCID to newborn screening panels

The Immune Deficiency Foundation commends the states of Maine and Rhode Island for adding Severe Combined Immune Deficiency to their states' newborn screening panels, effective August 1, 2014. These states join 21 other states currently screening newborns for SCID, ensuring over two thirds of all babies in the U.S. are now being screened. [More]
Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). [More]
Blood-forming stem cell transplantation benefits infants with severe combined immunodeficiency

Blood-forming stem cell transplantation benefits infants with severe combined immunodeficiency

Babies who are born with severe combined immunodeficiency (SCID) can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering's Richard J. O'Reilly, MD, a world-renowned pioneer in the development of transplant protocols. [More]
FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. [More]
EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union. [More]
EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union. [More]
Scientist develops highly accurate device for diagnosing fatal lung disease

Scientist develops highly accurate device for diagnosing fatal lung disease

A scientist from the University of Exeter has developed a simple, cheap and highly accurate device for diagnosing a frequently fatal lung disease which attacks immune deficient individuals such as cancer patients and bone marrow transplant recipients. [More]
Scientists develop next-generation platelet bioreactor to generate functional human platelets

Scientists develop next-generation platelet bioreactor to generate functional human platelets

Scientists at Brigham and Women's Hospital (BWH) have developed a scalable, next-generation platelet bioreactor to generate fully functional human platelets in vitro. The work is a major biomedical advancement that will help address blood transfusion needs worldwide. [More]
RPCI redesignated as Blue Distinction Center for delivering quality transplant care

RPCI redesignated as Blue Distinction Center for delivering quality transplant care

BlueCross BlueShield of Western New York today has redesignated Roswell Park Cancer Institute (RPCI) as a Blue Distinction Center® for delivering quality transplant care as part of the Blue Distinction Centers for Specialty Care® program. [More]
Citalopram can increase efficacy of BMSCs differentiating into neuronal-like cells

Citalopram can increase efficacy of BMSCs differentiating into neuronal-like cells

There is evidence that selective serotonin reuptake inhibitor antidepressants can promote neuronal cell proliferation and enhance neuroplasticity both in vitro and in vivo. [More]
Study: Stress can disrupt process of fat tissue development

Study: Stress can disrupt process of fat tissue development

Using experimental models, researchers at Boston University School of Medicine (BUSM) showed that adenosine, a metabolite released when the body is under stress or during an inflammatory response, stops the process of adipogenesis, when adipose (fat) stem cells differentiate into adult fat cells. [More]
Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. [More]
New genetic programs for taking blank-slate stem cells and turning them into human blood

New genetic programs for taking blank-slate stem cells and turning them into human blood

The ability to reliably and safely make in the laboratory all of the different types of cells in human blood is one key step closer to reality. [More]
NeoGenomics launches 23 NGS-based NeoTYPE Cancer Profiles

NeoGenomics launches 23 NGS-based NeoTYPE Cancer Profiles

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE Cancer Profiles based on next-generation sequencing (NGS). [More]
New mouse model supports transplantation of human blood stem cells without need for irradiation

New mouse model supports transplantation of human blood stem cells without need for irradiation

A novel mouse model allows for the transplantation of human blood-forming stem cells without the need for irradiation therapy.For many years scientists have been trying to unravel mechanisms that guide function and differentiation of blood stem cells, those cells that generate all blood cells including our immune system. [More]
Sigma-Tau Rare Disease seeks EMA approval for use of Oncaspar for ALL treatment

Sigma-Tau Rare Disease seeks EMA approval for use of Oncaspar for ALL treatment

Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen. [More]
Immune marker predicts infection risk in critically ill children with traumatic injuries

Immune marker predicts infection risk in critically ill children with traumatic injuries

Researchers studying critically ill children with traumatic injuries have identified an immune marker that predicts which patients are likely to develop a hospital-acquired infection. [More]
New gene therapy may be effective for fighting fungal infections in cancer patients

New gene therapy may be effective for fighting fungal infections in cancer patients

Sleeping Beauty and fungal infections - not two items one would normally associate together, but for immunocompromised cancer patients they may prove to be a helpful combination. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]